Trina Racine

University of Saskatchewan - Vaccine and Infectious Disease Organization

Saskatoon

Canada

SCHOLARLY PAPERS

2

DOWNLOADS

157

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 28 Posted: 21 Aug 2024
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 113 (529,927)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

2.

Efficacy of a Stable Broadly Protective Subunit Vaccine Platform Against Sars-Cov-2 Variants of Concern

Number of pages: 43 Posted: 18 Apr 2024
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 44 (902,171)

Abstract:

Loading...

SARS-CoV-2, subunit vaccine, broad protection, vaccine platform, emerging coronaviruses, Syrian hamsters